ArborGen posts HY22 continuing-ops loss as revenue falls 61% but FY22 EBITDA...

What changed

Revenue fell to NZ$4.6m from NZ$11.9m (-61.3%) and PBT swung to a NZ$0.9m loss from a NZ$3.6m profit. NPAT of NZ$0.1m (vs NZ$4.0m) was effectively held above zero only by a NZ$0.6m after-tax gain from discontinued operations (the ANZ business), with continuing operations posting a NZ$0.5m net loss. Operating cash flow collapsed to NZ$0.1m from NZ$3.4m, and with capex rising to NZ$1.9m from NZ$0.7m, pre-lease free cash flow swung from +NZ$2.7m to -NZ$1.8m. Cash fell to NZ$3.9m from NZ$5.1m, while gross borrowings reduced to NZ$33.8m from NZ$37.4m, leaving net debt modestly improved at NZ$29.9m.

What matters

• PBT is the cleaner read, and it is negative. NPAT benefits from a NZ$0.6m discontinued-operations line and a NZ$0.4m tax benefit on the loss (implied 44.4% benefit rate). The -125% PBT move, not the -97.5% NPAT move, is the right lens on operating performance.
• Seasonality materially reframes the optics. HY21 delivered only 22.6% of FY21 revenue of NZ$52.7m, confirming a heavily second-half-weighted profile. Annualising HY22 (NZ$9.2m) against FY21 (NZ$52.7m) overstates the deterioration, but the half-on-half revenue halving is still a genuine step-down requiring a very large 2H.
• Capital intensity stepped up. Capex rose to 41.3% of revenue from 5.9%, including NZ$1.4m in intellectual-property investment, signalling the core MCP/advanced-genetics strategy is being funded even as top-line is trough-seasonal.

Expectations

The company re-confirmed FY22 US GAAP EBITDA guidance of US$11.3m-US$11.7m, broadly in line with the FY21 anchor of NZ$11.3m. With HY21 representing only ~23% of FY21 revenue, a weak HY22 is not automatically inconsistent with that guide, but it leaves essentially the entire EBITDA target dependent on 2H delivery. Management pointed to year-to-date MCP order momentum (US private landowner MCP sales "projected to be up more than 45%") and growth in Brazil as the bridge; no forward-work balance was quantified. No explicit top-line target was provided, so the investor read is binary on whether the 2H shape matches prior years.

Quality of result

Low. The headline NPAT is flattered by the NZ$0.6m discontinued-operations contribution and a tax benefit on the loss, without which continuing operations was loss-making. Operating cash conversion deteriorated materially — OCF of NZ$0.1m against NZ$3.4m a year earlier — and with capex lifting, free cash flow turned negative. Inventories declined NZ$2.8m (to NZ$41.4m) and receivables fell, so working capital did not obscure an operating weakness; the earnings gap is operational and timing-driven rather than balance-sheet-assisted. Leverage is directionally better but only because absolute debt was paid down, not because earnings expanded.

Unresolved

• What share of the HY22 revenue gap reflects removal of the ANZ (discontinued) business versus underlying seasonality versus genuine softness in continuing operations? No clean like-for-like continuing-operations revenue bridge was disclosed.
• How much of the NZ$1.4m IP investment is capitalised R&D versus capitalised product cost, and what is the recurring vs one-off split within capex at 41% of half-year revenue?
• With no forward order book quantified, what is the evidence base supporting the reiterated FY22 US GAAP EBITDA range given the apparent pace through HY22?
• Are there any covenant headroom implications given NZ$33.8m of gross borrowings against NZ$3.9m of cash and negative pre-lease FCF in the half?

This briefing cannot assess the credibility of the FY22 US GAAP EBITDA guidance range because the release provides no quantified 2H order book, segment P&L, or statutory-to-non-GAAP reconciliation on which to test it.

Key metrics

Analytical metrics

This analysis was generated using Annolyse, an AI-powered tool that analyses NZX company announcements. The analysis is based on available company filings and standard Annolyse calculations. This is general information only and does not constitute financial advice. The analysis may contain errors. Always read the original company filings and consult a licensed financial adviser before making investment decisions.